Targeting human apurinic/apyrimidinic endonuclease 1 (APE1) in phosphatase and tensin homolog (PTEN) deficient melanoma cells for personalized therapy
Rachel Abbotts(University of Nottingham), Srinivasan Madhusudan(Nottingham University Hospitals NHS Trust), Claire Seedhouse(University of Nottingham), Jérémie Nsengimana(University of Leeds), Anna M. Grabowska(Silesian University of Technology), Poulam M. Patel(Nottingham University Hospitals NHS Trust), Faye Elliott(University of Leeds), Anton Simeonov(National Institutes of Health), Ajit Jadhav(National Institutes of Health), David M. Wilson(Hasselt University), David J. Maloney(National Institutes of Health), Julia Newton‐Bishop(University of Leeds), Jon Laye(University of Leeds), Graham Ball(Computer Algorithms for Medicine), Christy Walker(University of Leeds), Rosalyn Jewell
Cited by 51
Related Papers
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Hallmarks of neurodegenerative diseases
|Cell|2023|1.6k
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
|The Lancet Oncology|2013|605
Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline – Update 2016
|European Journal of Cancer|2016|579